BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33422771)

  • 1. Preclinical evaluation of [
    Lien VT; Celen S; Nuruddin S; Attili B; Doumont G; Van Simaeys G; Bormans G; Klaveness J; Olberg DE
    Nucl Med Biol; 2021 Feb; 93():74-80. PubMed ID: 33422771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo evaluation of (18)F-labeled TCO for pre-targeted PET imaging in the brain.
    Wyffels L; Thomae D; Waldron AM; Fissers J; Dedeurwaerdere S; Van der Veken P; Joossens J; Stroobants S; Augustyns K; Staelens S
    Nucl Med Biol; 2014 Jul; 41(6):513-23. PubMed ID: 24768149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and preclinical evaluation of a selective MET kinase positron emission tomography tracer.
    Lien VT; Hauge E; Nuruddin S; Klaveness J; Olberg DE
    J Labelled Comp Radiopharm; 2023 Dec; 66(14):452-460. PubMed ID: 37867318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-step synthesis of [
    Lien VT; Klaveness J; Olberg DE
    J Labelled Comp Radiopharm; 2018 Jan; 61(1):11-17. PubMed ID: 28921623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Evaluation of
    Declercq L; Rombouts F; Koole M; Fierens K; Mariën J; Langlois X; Andrés JI; Schmidt M; Macdonald G; Moechars D; Vanduffel W; Tousseyn T; Vandenberghe R; Van Laere K; Verbruggen A; Bormans G
    J Nucl Med; 2017 Jun; 58(6):975-981. PubMed ID: 28232614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors.
    Slobbe P; Windhorst AD; Stigter-van Walsum M; Schuit RC; Smit EF; Niessen HG; Solca F; Stehle G; van Dongen GA; Poot AJ
    Nucl Med Biol; 2014 Oct; 41(9):749-57. PubMed ID: 25066021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of [(18)F]JNJ42259152 as a PET tracer for PDE10A.
    Celen S; Koole M; Ooms M; De Angelis M; Sannen I; Cornelis J; Alcazar J; Schmidt M; Verbruggen A; Langlois X; Van Laere K; Andrés JI; Bormans G
    Neuroimage; 2013 Nov; 82():13-22. PubMed ID: 23664955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
    Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F
    Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Utility of [
    Beinat C; Haywood T; Chen YS; Patel CB; Alam IS; Murty S; Gambhir SS
    Mol Imaging Biol; 2018 Dec; 20(6):1015-1024. PubMed ID: 29736561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries.
    Doran MG; Spratt DE; Wongvipat J; Ulmert D; Carver BS; Sawyers CL; Evans MJ
    Mol Imaging; 2014; 13():. PubMed ID: 25248353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.
    Ganguly T; Dannoon S; Hopkins MR; Murphy S; Cahaya H; Blecha JE; Jivan S; Drake CR; Barinka C; Jones EF; VanBrocklin HF; Berkman CE
    Nucl Med Biol; 2015 Oct; 42(10):780-7. PubMed ID: 26169882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms.
    Scott AJ; Arcaroli JJ; Bagby SM; Yahn R; Huber KM; Serkova NJ; Nguyen A; Kim J; Thorburn A; Vogel J; Quackenbush KS; Capasso A; Schreiber A; Blatchford P; Klauck PJ; Pitts TM; Eckhardt SG; Messersmith WA
    Mol Cancer Ther; 2018 Oct; 17(10):2112-2122. PubMed ID: 30026382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
    Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
    Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer.
    Kwan KH; Burvenich IJG; Centenera MM; Goh YW; Rigopoulos A; Dehairs J; Swinnen JV; Raj GV; Hoy AJ; Butler LM; Scott AM; White JM; Ackermann U
    Nucl Med Biol; 2021 Feb; 93():37-45. PubMed ID: 33310350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and in vivo preclinical evaluation of an (18)F labeled uPA inhibitor as a potential PET imaging agent.
    Ides J; Thomae D; Wyffels L; Vangestel C; Messagie J; Joossens J; Lardon F; Van der Veken P; Augustyns K; Stroobants S; Staelens S
    Nucl Med Biol; 2014 Jul; 41(6):477-87. PubMed ID: 24768145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiofluorinated probe for PET imaging of fatty acid binding protein 4 in cancer.
    Temma T; Nishigori K; Onoe S; Sampei S; Kimura I; Ono M; Saji H
    Nucl Med Biol; 2015 Feb; 42(2):184-91. PubMed ID: 25457456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [
    Amor-Coarasa A; Kelly J; Ponnala S; Vedvyas Y; Nikolopoulou A; Williams C; Jin MM; David Warren J; Babich JW
    Nucl Med Biol; 2018 May; 60():37-44. PubMed ID: 29544122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography.
    Iommelli F; De Rosa V; Gargiulo S; Panico M; Monti M; Greco A; Gramanzini M; Ortosecco G; Fonti R; Brunetti A; Del Vecchio S
    Clin Cancer Res; 2014 Sep; 20(18):4806-15. PubMed ID: 25052479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological evaluation of 3-[(18)F]fluoro-α-methyl-D-tyrosine (D-[(18)F]FAMT) as a novel amino acid tracer for positron emission tomography.
    Ohshima Y; Hanaoka H; Tominaga H; Kanai Y; Kaira K; Yamaguchi A; Nagamori S; Oriuchi N; Tsushima Y; Endo K; Ishioka NS
    Ann Nucl Med; 2013 May; 27(4):314-24. PubMed ID: 23337966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.